Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 379 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR The Unique Challenges Teenagers and Young Adults With Cancer Face: An... January 4, 2021 High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... June 15, 2021 How to Tell If Cancer Information on Social Media Is “Fake... September 29, 2020 FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer April 14, 2021 Load more HOT NEWS Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without... Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... Adding Upfront SRS to CNS-penetrant TKI Improves Time-to-CNS Progression and Local... Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable...
